FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997186363> ?p ?o ?g. }

• W1997186363 endingPage "553" @default.
• W1997186363 startingPage "553" @default.
• W1997186363 abstract "The antioxidant acetylcysteine prevents acute contrast nephrotoxicity in patients with impaired renal function who undergo computed tomography scanning. However, its role in coronary angiography is unclear.To determine whether oral acetylcysteine prevents acute deterioration in renal function in patients with moderate renal insufficiency who undergo elective coronary angiography.Prospective, randomized, double-blind, placebo-controlled trial conducted from May 2000 to December 2001 at the Grantham Hospital at the University of Hong Kong.Two hundred Chinese patients aged mean (SD) 68 (6.5) years with stable moderate renal insufficiency (creatinine clearance <60 mL/min [1.00 mL/s]) who were undergoing elective coronary angiography with or without intervention.Participants were randomly assigned to receive oral acetylcysteine(600 mg twice per day; n = 102) or matching placebo tablets (n = 98) on the day before and the day of angiography. All patients received low-osmolality contrast agent.Occurrence of more than a 25% increase in serum creatinine level within 48 hours after contrast administration; change in creatinine clearance and serum creatinine level.Twelve control patients (12%) and 4 acetylcysteine patients (4%) developed a more than 25% increase in serum creatinine level within 48 hours after contrast administration (relative risk, 0.32; 95% confidence interval [CI], 0.10-0.96; P =.03). Serum creatinine was lower in the acetylcysteine group (1.22 mg/dL [107.8 micromol/L]; 95% CI, 1.11-1.33 mg/dL vs 1.38 mg/dL [122.9 micromol/L]; 95% CI, 1.27-1.49 mg/dL; P =.006) during the first 48 hours after angiography. Acetylcysteine treatment significantly increased creatinine clearance from 44.8 mL/min (0.75 mL/s) (95% CI, 42.7-47.6 mL/min) to 58.9 mL/min (0.98 mL/s) (95% CI, 55.6-62.3 mL/min) 2 days after the contrast administration (P<.001). The increase was not significant in the control group (from 42.1 to 44.1 mL/min [0.70 to 0.74 mL/s]; P =.15). The benefit of acetylcysteine was consistent among various patient subgroups and persistent for at least 7 days. There were no major treatment-related adverse events.Acetylcysteine protects patients with moderate chronic renal insufficiency from contrast-induced deterioration in renal function after coronary angiographic procedures, with minimal adverse effects and at a low cost." @default.
• W1997186363 created "2016-06-24" @default.
• W1997186363 creator A5000092593 @default.
• W1997186363 creator A5001477007 @default.
• W1997186363 creator A5012396609 @default.
• W1997186363 creator A5028346592 @default.
• W1997186363 creator A5045322868 @default.
• W1997186363 creator A5065649607 @default.
• W1997186363 creator A5076880854 @default.
• W1997186363 creator A5083131182 @default.
• W1997186363 creator A5084467163 @default.
• W1997186363 date "2003-02-05" @default.
• W1997186363 modified "2023-10-17" @default.
• W1997186363 title "Acetylcysteine for Prevention of Acute Deterioration of Renal Function Following Elective Coronary Angiography and Intervention" @default.
• W1997186363 cites W1550111394 @default.
• W1997186363 cites W1943657666 @default.
• W1997186363 cites W1965147464 @default.
• W1997186363 cites W1966668260 @default.
• W1997186363 cites W1986646646 @default.
• W1997186363 cites W2011500053 @default.
• W1997186363 cites W2017231977 @default.
• W1997186363 cites W2018224788 @default.
• W1997186363 cites W2027695475 @default.
• W1997186363 cites W2029723446 @default.
• W1997186363 cites W2040005638 @default.
• W1997186363 cites W2041438931 @default.
• W1997186363 cites W2042074736 @default.
• W1997186363 cites W2048423674 @default.
• W1997186363 cites W2055875089 @default.
• W1997186363 cites W2070765066 @default.
• W1997186363 cites W2084064269 @default.
• W1997186363 cites W2084381603 @default.
• W1997186363 cites W2088811748 @default.
• W1997186363 cites W2091515137 @default.
• W1997186363 cites W2115973039 @default.
• W1997186363 cites W2129892232 @default.
• W1997186363 cites W2135915671 @default.
• W1997186363 cites W2151040702 @default.
• W1997186363 cites W2154563701 @default.
• W1997186363 cites W2159718794 @default.
• W1997186363 cites W2321031842 @default.
• W1997186363 cites W2327454703 @default.
• W1997186363 cites W2330776976 @default.
• W1997186363 cites W4230856064 @default.
• W1997186363 cites W4249999102 @default.
• W1997186363 doi "https://doi.org/10.1001/jama.289.5.553" @default.
• W1997186363 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12578487" @default.
• W1997186363 hasPublicationYear "2003" @default.
• W1997186363 type Work @default.
• W1997186363 sameAs 1997186363 @default.
• W1997186363 citedByCount "419" @default.
• W1997186363 countsByYear W19971863632012 @default.
• W1997186363 countsByYear W19971863632013 @default.
• W1997186363 countsByYear W19971863632014 @default.
• W1997186363 countsByYear W19971863632015 @default.
• W1997186363 countsByYear W19971863632016 @default.
• W1997186363 countsByYear W19971863632017 @default.
• W1997186363 countsByYear W19971863632018 @default.
• W1997186363 countsByYear W19971863632019 @default.
• W1997186363 countsByYear W19971863632020 @default.
• W1997186363 countsByYear W19971863632021 @default.
• W1997186363 countsByYear W19971863632022 @default.
• W1997186363 countsByYear W19971863632023 @default.
• W1997186363 crossrefType "journal-article" @default.
• W1997186363 hasAuthorship W1997186363A5000092593 @default.
• W1997186363 hasAuthorship W1997186363A5001477007 @default.
• W1997186363 hasAuthorship W1997186363A5012396609 @default.
• W1997186363 hasAuthorship W1997186363A5028346592 @default.
• W1997186363 hasAuthorship W1997186363A5045322868 @default.
• W1997186363 hasAuthorship W1997186363A5065649607 @default.
• W1997186363 hasAuthorship W1997186363A5076880854 @default.
• W1997186363 hasAuthorship W1997186363A5083131182 @default.
• W1997186363 hasAuthorship W1997186363A5084467163 @default.
• W1997186363 hasBestOaLocation W19971863631 @default.
• W1997186363 hasConcept C126189478 @default.
• W1997186363 hasConcept C126322002 @default.
• W1997186363 hasConcept C126894567 @default.
• W1997186363 hasConcept C141071460 @default.
• W1997186363 hasConcept C142724271 @default.
• W1997186363 hasConcept C159641895 @default.
• W1997186363 hasConcept C185592680 @default.
• W1997186363 hasConcept C204787440 @default.
• W1997186363 hasConcept C27081682 @default.
• W1997186363 hasConcept C2777847592 @default.
• W1997186363 hasConcept C2778004101 @default.
• W1997186363 hasConcept C2778569047 @default.
• W1997186363 hasConcept C2780091579 @default.
• W1997186363 hasConcept C2780306776 @default.
• W1997186363 hasConcept C2780400711 @default.
• W1997186363 hasConcept C2780472472 @default.
• W1997186363 hasConcept C2780643987 @default.
• W1997186363 hasConcept C44249647 @default.
• W1997186363 hasConcept C500558357 @default.
• W1997186363 hasConcept C55493867 @default.
• W1997186363 hasConcept C71924100 @default.
• W1997186363 hasConcept C90924648 @default.
• W1997186363 hasConceptScore W1997186363C126189478 @default.
• W1997186363 hasConceptScore W1997186363C126322002 @default.

• next